Always at the front of new developments

As pioneers, our team managed to achieve market access for the first immunotherapy and first ATMP, alongside managing new assessment procedures for GRADE and LOCK. We acquired GRADE-experience for (orphan) medicinal products, and achieved in-hospital financing through DRGs (DBCs) for ‘first in its class technologies’ in orthopedic surgery and oncology.